Clinical features and response to current treatment modalities in mantle cell lymphoma
This chapter addresses the important question of whether mantle cell lymphoma should be excluded from the indolent or low grade lymphomas, and presents strong evidence that it should be [10.1].
KeywordsLymphoma Oncol Stein Anthracycline Phoma
Unable to display preview. Download preview PDF.
- 1.Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85: 1075–82.PubMedGoogle Scholar
- 3.Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819–26.PubMedGoogle Scholar
© Springer-Verlag London 1999